Congress Investigates ActBlue Amid Fundraising Scrutiny
Congressional investigators are deepening their inquiry into ActBlue, a major fundraising platform for the Democratic Party, by seeking interviews with board members due to mounting concerns about its management of foreign donations.
Republican chairmen from three House committees are urging five ActBlue board members to voluntarily provide interview transcripts and a comprehensive set of documents regarding their role in the organization’s response to allegations of donor fraud.
They have set a deadline of June 16 for the board members to comply, according to a letter that was examined recently. This request comes at a time when ActBlue faces increased scrutiny surrounding its anti-fraud measures and the accuracy of its reporting on foreign donations potentially linked to U.S. elections. The committee has claimed that the organization is not being transparent and is hindering the investigation by withholding requested documents.
In their letter, House Administration Committee Chairman Brian Steil (R-Wis.), House Oversight Committee Chairman James Comer (R-Ky.), and House Judiciary Committee Chairman Jim Jordan (R-Ohio) expressed concern that the board might have been complicit or aware of misconduct. They requested the board’s cooperation for oversight purposes.
So far, ActBlue has not issued a comment. However, the scrutiny is intensifying as the platform’s CEO, Regina Wallace-Jones, is expected to testify before the House Administration Committee on June 10, discussing foreign donation practices.
Steil suggested that Wallace-Jones may have misled the committee at the beginning of the investigation regarding the company’s anti-fraud policies, emphasizing the need to clarify the situation and provide answers to the public.
Reports indicate that ActBlue’s own legal team has raised questions about whether the platform accurately described its anti-fraud measures to Congress. An early 2025 warning from outside counsel Covington & Burling warned Wallace-Jones that some statements she made may have been misleading regarding how the platform assesses potentially illegal donations from foreign sources.
Furthermore, it appears that ActBlue did not immediately disclose that certain procedures for reviewing fraudulent donations were not consistently enforced as previously claimed to investigators. This raises serious questions about their transparency.
A recent letter from ActBlue’s new outside counsel acknowledged that improvements had been made to donor screening procedures only after these concerns were flagged. ActBlue’s board chair, Kimberly Peeler Allen, commented that the decision to enhance procedures stemmed from a desire not to provoke unnecessary scrutiny from Congress.
Peeler Allen is also facing interview requests from Republican lawmakers. The board’s response to several high-profile resignations and allegations of retaliation related to claims of misinformation submitted to Congress are under examination, too. Notably, ActBlue’s lawyers lost access to the company’s computer systems after attempting to alert the board about potential legal complications.
The unions within ActBlue have expressed concerns about instability within the organization, suggesting that frequent changes in personnel are damaging overall confidence in its management.
While ActBlue maintains its stance of innocence and has not faced criminal charges, a spokesperson has characterized the Congressional probe as a Republican effort to undermine a crucial element of the Democratic Party’s financial framework, especially ahead of the upcoming midterm elections.
